Investor Relations Overview

NeoGenomics, Inc. is a high-complexity CLIA—certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry.  The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology and molecular genetic testing.  Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA, Tampa, FL and Fort Myers, FL.  NeoGenomics services the needs of pathologists, oncologists, other clinicians and hospitals throughout the United States. For additional information about NeoGenomics, visit neogenomics.com.  

NeoGenomics (NASDAQ: NEO) 4:00 PM ET on May 23, 2013
Last Price Change Open Day High 52-Week High
3.78
0.08  up   (2.162%) 3.67 3.79 4.20
Volume Previous Close Day Low 52-Week Low
70,300 3.70 3.60 1.55

 
Stock price graph

The stock information provided is for informational purposes only and is not intended for trading purposes. The stock information is provided by eSignal, stock charts are provided by EDGAR Online, both third party services, and NeoGenomics does not maintain or provide information directly to this service. Stock information is delayed approximately 20 minutes.

Company Overview Presentation

Download our Company Overview Presentation

View all »   RSSFinancial News

Apr 25, 2013
NeoGenomics Reports Record Quarterly Revenue of $15.7 Million, Adjusted EBITDA of $1.8 Million and 46.3% Gross Margin for the First Quarter

Apr 17, 2013
NeoGenomics Schedules its Q1 2013 Earnings Release for April 25, 2013

Feb 28, 2013
NeoGenomics Announces Pricing of $9.5 Million Public Offering

View all »Events & Presentations

May 29, 2013
Craig-Hallum Capital Group LLC Institutional Investor Conference

May 30, 2013
38th Annual Deutsche Bank dbAccess Health Care Conference